Stereotactic Radiosurgery for Intracranial Ependymomas: An International Multicenter Study
Jazyk angličtina Země Spojené státy americké Médium print
Typ dokumentu časopisecké články, multicentrická studie, práce podpořená grantem
PubMed
29608701
DOI
10.1093/neuros/nyy082
PII: 4955825
Knihovny.cz E-zdroje
- MeSH
- dítě MeSH
- doba přežití bez progrese choroby MeSH
- dospělí MeSH
- ependymom mortalita chirurgie MeSH
- kombinovaná terapie metody MeSH
- lidé středního věku MeSH
- lidé MeSH
- lokální recidiva nádoru mortalita chirurgie MeSH
- mladiství MeSH
- mladý dospělý MeSH
- nádory mozku mortalita chirurgie MeSH
- předškolní dítě MeSH
- progrese nemoci MeSH
- radiochirurgie škodlivé účinky metody mortalita MeSH
- retrospektivní studie MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- výsledek terapie MeSH
- Check Tag
- dítě MeSH
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- předškolní dítě MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
BACKGROUND: Stereotactic radiosurgery (SRS) is a potentially important option for intracranial ependymoma patients. OBJECTIVE: To analyze the outcomes of intracranial ependymoma patients who underwent SRS as a part of multimodality management. METHODS: Seven centers participating in the International Gamma Knife Research Foundation identified 89 intracranial ependymoma patients who underwent SRS (113 tumors). The median patient age was 16.3 yr (2.9-80). All patients underwent previous surgical resection and radiation therapy (RT) of their ependymomas and 40 underwent previous chemotherapy. Grade 2 ependymomas were present in 42 patients (52 tumors) and grade 3 ependymomas in 48 patients (61 tumors). The median tumor volume was 2.2 cc (0.03-36.8) and the median margin dose was 15 Gy (9-24). RESULTS: Forty-seven (53%) patients were alive and 42 (47%) patients died at the last follow-up. The overall survival after SRS was 86% at 1 yr, 50% at 3 yr, and 44% at 5 yr. Smaller total tumor volume was associated with longer overall survival (P = .006). Twenty-two patients (grade 2: n = 9, grade 3: n = 13) developed additional recurrent ependymomas in the craniospinal axis. The progression-free survival after SRS was 71% at 1 yr, 56% at 3 yr, and 48% at 5 yr. Adult age, female sex, and smaller tumor volume indicated significantly better progression-free survival. Symptomatic adverse radiation effects were seen in 7 patients (8%). CONCLUSION: SRS provides another management option for residual or recurrent progressive intracranial ependymoma patients who have failed initial surgery and RT.
Department of Neurosurgery Cleveland Clinic Foundation Cleveland Ohio
Department of Neurosurgery Taipei Veteran General Hospital Taipei Taiwan
Department of Neurosurgery University of Virginia Charlottesville Virginia
Division of Neurosurgery Université de Sherbrooke Centre de Recherche du CHUS Sherbrooke Canada
Section of Neurosurgery University of Manitoba Canada
Stereotactic and Radiation Neurosurgery Na Homolce Hospital Prague Czech
Citace poskytuje Crossref.org
